Merck KGaA Partners in Big Data
Merck KGaA has partnered with Palantir Technologies, a developer of data integration and analysis software headquartered in Palo Alto, California, to use Palantir’s data analytics capabilities to help Merck develop and deliver medicines to patients, commercialize new products, and improve patient outcomes.
Merck will initially apply Palantir’s technology to cancer treatments and patient services, but plans to deploy the technology across all three of Merck’s business sectors: healthcare, life science, and performance materials. Financial details were not disclosed.
The partnership will launch with three initiatives within Merck’s healthcare business sector: medical research and drug development, global patient intimacy, and global supply chain. In the healthcare business sector, the partnership will increase precision of the drug development process by developing a collaborative data and analytics platform so that Merck researchers can analyze real-world and bioinformatics data. In the global patient intimacy business sector, the partnership aims to improve the experience of patients by utilizing large-scale data sources to increase adherence and understand real-world drug efficacy. In the global supply-chain business sector, the data and analytics platform is expected to improve supply chain forecasting and agility.
Source: Merck KGaA